Skip to main content
Biomolecules logoLink to Biomolecules
. 2020 Aug 12;10(8):1173. doi: 10.3390/biom10081173

Computational Identification and Characterization of New microRNAs in Human Platelets Stored in a Blood Bank

Jersey Heitor da Silva Maués 1,2,*,, Caroline de Fátima Aquino Moreira-Nunes 3,*,, Rommel Mário Rodriguez Burbano 1,2
PMCID: PMC7464399  PMID: 32806499

Abstract

Platelet concentrate (PC) transfusions are widely used to save the lives of patients who experience acute blood loss. MicroRNAs (miRNAs) comprise a class of molecules with a biological role which is relevant to the understanding of storage lesions in blood banks. We used a new approach to identify miRNAs in normal human platelet sRNA-Seq data from the GSE61856 repository. We identified a comprehensive miRNA expression profile, where we detected 20 of these transcripts potentially expressed in PCs stored for seven days, which had their expression levels analyzed with simulations of computational biology. Our results identified a new collection of miRNAs (miR-486-5p, miR-92a-3p, miR-103a-3p, miR-151a-3p, miR-181a-5p, and miR-221-3p) that showed a sensitivity expression pattern due to biological platelet changes during storage, confirmed by additional quantitative real-time polymerase chain reaction (qPCR) validation on 100 PC units from 500 healthy donors. We also identified that these miRNAs could transfer regulatory information on platelets, such as members of the let-7 family, by regulating the YOD1 gene, which is a deubiquitinating enzyme highly expressed in platelet hyperactivity. Our results also showed that the target genes of these miRNAs play important roles in signaling pathways, cell cycle, stress response, platelet activation and cancer. In summary, the miRNAs described in this study, have a promising application in transfusion medicine as potential biomarkers to also measure the quality and viability of the PC during storage in blood banks.

Keywords: platelet concentrate, microRNA, sRNA-seq, storage lesions, platelet hyperactivity

1. Introduction

Platelet concentrate (PC) transfusions are widely used to save the lives of patients suffering from acute blood loss and are more often used in supportive prophylactic therapy for patients with various hematological diseases [1].

This blood component requires special storage in blood banks, normally being stored up to a maximum of five days at a temperature of 22 ± 2 °C, with gentle and continuous agitation, because even under ideal storage conditions, the PC can undergo modifications or degradations known as platelet storage lesion (PSL), a term introduced by Murphy et al., in 1971 [2], for describing the multifactorial mechanisms of this problem, which include the methods of collection, processing, storage, handling before or after collection, and expiration date [3,4,5]. In Brazil, the validity of the PC is three to seven days, depending on the plasticizer of the conservation bag [6]. More generally, the storage time of the PC depends on local legislation and the additive solution, regarding whether or not to use a pathogen inactivator [7,8].

Longer platelet storage duration has not been recommended due to the possible risk of bacterial contamination. Therefore, research on updating screening of molecular biomarkers to assess and monitor the physiological viability of platelets in PC has gained strength in recent years, mainly to identify PSL [9,10].

The most common changes in platelets during storage in PCs are morphological and physiological changes, platelet activation related to exposure to foreign surfaces, trauma, low pH, platelet agonists such as thrombin and ADP, promoting changes in membrane glycoproteins, proteolysis, and expression of platelet surface receptors, culminating in the release of microparticles (MPs) rich in microRNAs (miRNAs) [5,10,11,12,13,14,15]. Tests of mitochondrial dysfunction show that the overall bioenergetic health of stored platelets is significantly lower as compared with fresh platelets, suggesting that stored platelets are more susceptible to oxidative stress [16,17] and apoptosis [10,18].

MicroRNAs (miRNAs) comprise a class of molecules with a biological role capable of acting together to mediate sequence-specific regulation by repressing or degrading mRNAs at specific non-translated binding sites [19] and are a relevant tool for understanding storage lesions, proven by studies on stored platelets that continue to translate mRNA proteins [20,21,22,23]. Platelets contain an abundance of RNAs, miRNAs and have fully functional mRNA splicing machinery. In this context, platelet miRNAs can regulate the levels of expression of platelet mRNA and, consequently, proteins [24,25,26].

Our previous studies have shown miRNAs to be a promising tool for measuring the quality of PCs stored in blood banks. We found that the inverse expression relationship between miR-127 and miR-320a allowed us to identify PC bags that could still have physiologically normal (non-activated) platelets [20]. In addition, we identified another 14 miRNAs expressed differentially, comparing a control PC from the first day of storage with the PCs on each of the subsequent five days of storage from day one to day seven [21]. In this study, we used a new approach with bioinformatics and computational biology methods to identify and characterize the profile of new miRNAs and their sequence variants in platelet concentrates stored for seven days in a blood bank.

2. Methods

2.1. Dataset Analysis

In this study, we used the data available in the Gene Expression Omnibus (GEO) database with accession number GSE61856, studied by Pontes et al. [20]. The data were generated with small RNA-sequencing (sRNA-Seq) from PCs using an Illumina HiSeq 2000 platform. In this experiment, sixteen PC bags tubes were used, then, cut into six equal parts and maintained for seven days of storage. PC pooled miRNAs, sufficient to perform the sequencing, were extracted on each day of the seven days. The first day was the high-quality control of platelets and the seventh day was the low-quality control of platelets [20].

Human platelets were collected from healthy donors according to international standard protocols and stored at 22 ± 2 °C for 7 days. The small RNA population was evaluated after the first day (PC-1), the second day (PC-2), the third day (PC-3), the fourth day (PC-4), the fifth day (PC-5), and the seventh day (PC-7), of storage at 22 °C. Thus, small changes in the RNA population over the days were assessed with sRNA-Seq [20].

2.2. MicroRNAs Prediction in PCs

The SRA (sequence read archive) from the seven PC samples were downloaded from GSE61856 and used as input in the sRNAbench and sRNAtoolbox [27], latest version, updated in 2019. Reads generated with sRNA-Seq were processed with sRNAbench and showed high quality >90% in all six libraries.

We performed the reading mapping pipeline in genome and library mode, in which both modes used a common preprocessing step, mapping, expression profile, and miRNA prediction [28]. For this, the 3’ adapter sequence was trimmed, and the sequence length distribution was analyzed. Sequences with a reading length between 15 and 27 nucleotides (nt) were aligned with the miRNA precursor sequences (pre-miRNA) of human miRBase, version 22 [29].

To this analysis, we applied the standard sRNAbench parameters as follows: (i) minimum length of adapter that needs to be detected, 10; (ii) alignment type, Bowtie seed alignment (GRCh38_p10_mp), seed length for alignment 20, minimum read count 2, minimum read length 15, allowed number of mismatches 1, the maximum number of multiple mappings 10; (iii) MEAN quality filtering was used, 20; and (iv) the annotation used miRNAs for species hsa (Homo sapiens).

2.3. MicroRNA Expression and Quality Analysis between Different PCs

We assessed the level of miRNA expression by counting per million reads (CPM) using the following formula: CPM = (reads number of one miRNA)/(total mapped reads to all annotated miRNAs) × 106. We defined a miRNA expressed in a PC with a CPM > 1 in more than 50% of the six PC samples. The PC-specific miRNA was defined as a miRNA expressed exclusively in PC on the first day (PC-1), was used in this study as the platelet quality control.

Because PCs are stored in a blood bank for a maximum period that varies between three and five days, depending on the plasticizer in the conservation bag [6], our analyses considered the first day as the high-quality control of platelets and the seventh day corresponded to the low-quality control of platelets [20].

In our computational results obtained with sRNA-Seq, we analyzed miRNAs expressions according to the methodology described by Pontes et al. [20] to check which PC bags were in good condition for transfusion. This method compared the relative expression between miR-127 and miR-320a [30]. When miR-127 presented a lower expression (<80%) as compared with miR-320a, storage lesions in this blood component were considered, suggesting the blockage of the PC bag for transfusion.

The PC bag was considered to be suitable for transfusion when it had one of the following possibilities: (i) expression of miR-127 > miR-320a, (ii) equal expression between miR-127 and miR-320a, (iii) and a difference less than 20% in expression between these two miRNAs. In this study, the results generated for the expression levels of miRNAs were analyzed using computational biology simulations, employing unsupervised grouping and principal component analysis (PCA).

2.4. Validation of microRNAs by qPCR on 100 PC Units

Each PC which was used contained platelets from five healthy donors. Therefore, validation was performed in 500 donors (250 men and 250 women in the age group that comprises young adults, between 18 and 40 years old). All biosafety policy guidelines were applied in the involved laboratories, with the approval of the Ethics Committee (#194, 196, approval 17 October 2012).

Seven days of storage were analyzed, and the first day was used as the control for the following days, totaling five comparisons of expression levels for each of the six miRNAs identified, accounting for 30 analyses. As the validation occurred in 100 PC units, we totaled this validation in 3000 analyses. Mir-191 was selected as an internal control for miRNA input and reverse transcription efficiency because the miRNA was most highly expressed on seven different days of storage [20]. All real-time quantitative PCR (qPCR) reactions were performed in triplicate for both miRNAs. Expression levels of miR-486-5p, miR-92a-3p, miR-103a-3p, miR-151a-3p, miR-181a-5p, and miR-221-3p were isolated from 100 PC units with mirVanaTM miRNA Isolation Kit (Thermo Fisher Scientific, Waltham, MA, USA).

The miRNA was reverse transcribed using the TaqMan® MicroRNA Reverse Transcription Kit, according to the manufacturer’s protocol (Thermo Fisher Scientific, Waltham, MA, USA). The qPCR analyses were performed with TaqMan® microRNA assays (Thermo Fisher Scientific, Waltham, MA, USA) for miR-486-5p (ID 001278), miR-92a-3p (ID 000431), miR-103a-3p (ID 000439), miR-151a-3p (ID 002254), miR-181a-5p (ID 000480), miR-221-3p (ID 000524). Then, complementary DNA was amplified by qPCR using the TaqMan Universal Master Mix II with UNG (Thermo Fisher Scientific, Waltham, MA, USA) on a Rotor-Gene Q (Qiagen, Hilden, Germany).

2.5. IsomiR Annotation Analysis

In this analysis, we detected the miRNAs sequence variants called isomiR [31]. To detect isomiRs, we applied the following steps for the sRNAbench pipeline: (i) mapping the reads with the pre-microRNA genome or sequence using the Bowtie seed option [32], (ii) determining the coordinates of the mature microRNA, (iii) clustering of all reads that mapped within a window of the canonical sequence of the mature microRNA (miRBase), and (iv) applying a hierarchical classification of the variants [27].

Then, a subsequent analysis was performed to detect multiple NTA sequence variants which involved non-templated additions (enzymatically addition of a nucleotide to the 3′ end, i.e., adenylation and uridylation) that included NTA(A), number of reads with a non-templated A (adenine) addition; NTA(U), number of reads with a non-templated U (uracil) and (T) thymine addition; NTA(C), number of reads with a non-templated C (cytosine) addition; and NTA(G), number of reads with a non-templated G (guanine) addition.

The second class of length variants included 5′ and 3′ trimming and extension in the following forms: lv3pE, number of reads with 3′ length extension (longer than the canonical sequence); lv3pT, number of reads with 3′ length trimming (shorter than the canonical sequence); lv5pE, number of reads with 5’ length extension (longer than the canonical sequence); lv5pT, number of reads with 5′ length extension (shorter than the canonical sequence); and mv, number of reads classified as multiple length variants [28]. We organized the results of this analysis by the ranking of isomiRs identified in PCs and mature miRNA most expressed according to individual reading counts (CPM expression).

2.6. MicroRNAs Target Prediction

We investigated the possible target genes of the miRNAs most expressed in PC with the TargetScan algorithms, version 7.2 (http://www.targetscan.org/vert_72/), miRTarBase, version 8.0 (http://mirtarbase.cuhk.edu.cn/php/index.php), and miRDB, version 6.0 (http://www.mirdb.org/statistics.html), to identify possible miRNA–gene interactions. TargetScan is a predictor that generates predicted interactions, while miRTarBase and miRDB provide validated interactions [33,34,35].

For this analysis, we applied an information retrieval feature known as target mining in the miRWalk predictor, version 3.0 (http://mirwalk.umm.uni-heidelberg.de/), which hosts the three aforementioned predictors, to obtain the information from miRNA–gene interactions that were organized in a table with various predictive metrics, which were considered for binding probability (p > 0.95) [36], sites preferably conserved within the 3’ UTR (untranslated region) and validated interactions [37].

Three subsets of data were analyzed and listed as follows: (1) TargetScan + miRDB, (2) TargetScan + miRTarBase, and (3) miRDB + miRTarBase. For further investigative analysis, we considered the miRNA–gene interactions that were identified at the intersection of the Venn diagram of these three subsets. For this analysis, we used the Venny tool (https://bioinfogp.cnb.csic.es/tools/venny/).

2.7. Construction of the microRNA—Gene Interaction Network

The subset files containing the predicted and validated interactions, identified in the previous analysis, were used in the construction of miRNA–gene interaction networks. For that, we filtered only the predicted and validated interactions of interest to remove those annotated symbol genes for more than one Refseq identifier. Then, we simulated the construction of two miRNA–gene interaction networks for the two predicted and validated interaction files (1) and (2), respectively, which were loaded and viewed in Cytoscape, version 3.8.0 (https://cytoscape.org/).

The two networks were merged according to the tutorial (http://manual.cytoscape.org/en/stable/Merge.html) with an intersection operator to obtain a single miRNA–gene interaction network common to the two previous networks, formed exclusively by interaction data predicted and validated. The central region of the network with the densest connections was detected with CytoHubba [38]. We applied the maximal click centrality (MCC) method to identify miRNA–gene interaction clusters.

2.8. Functional Enrichment Analysis

The target genes of the miRNA–gene interaction network from the previous analysis were used for functional enrichment with the tool the Database for Annotation, Visualization and Integrated Discovery (DAVID, version v6.8) [39]. These target genes were organized in a list containing only the Refseq identifier of the species (Homo sapiens).

To avoid redundancies in terms, high-stringency classifiers with a similarity threshold and multiple linkage threshold equal to 0.50 were applied. The most significant terms for each gene were obtained from functional annotation clusters GO (Gene Ontology) [40] and from KEGG pathways (Kyoto Encyclopedia of Genes and Genomes) [41] with significant values noted with Log10, p-value < 0.05.

2.9. Statistical Analysis

All statistics were performed using R (https://www.r-project.org). The averages obtained with the non-parametric tests were calculated using the compare_means function. Principal component analysis (PCA) with the FactoMineR package [42] was used for exploratory investigation of multivariate data from miRNA using the prcomp function. The unsupervised grouping and heatmaps were built with the heatmap function.2. The correlation coefficients of the isomiRs were calculated with the following functions: cor and rcorr. Correlations with p-value > 0.01 were considered not significant. The ANOVA test was used to test the means among the miRNA variants.

3. Results

3.1. Data Preprocessing and Abundance of microRNAs in Platelet Concentrate

The results of sRNA-Seq analysis from PCs of the GSE61856 repository, made with sRNAbench, showed that after a preprocessing of the data, more than 95% of the reads were recovered, which mapped between 81 and 85% of unique regions of the genome, with coverage genomics comprised of 95%, (Table 1). We observed that the amount of read counts (RC) detected for miRBase hairpins showed a decrease from the fourth to the fifth day, increasing only on the last day. The same pattern was observed for mature miRNAs that presented more than 35% of miRNA expressed on the last day of storage (PC-7) (Table 1).

Table 1.

A summary of microRNA (miRNA) analysis in platelet concentrates.

Preprocessing Summary (PC-Day)
SRA:
PC-1 PC-2 PC-3 PC-4 PC-5 PC-7
SRX716593 SRX716594 SRX716595 SRX716596 SRX716597 SRX716598
Raw input reads 16,212,635 13,594,963 17,214,842 25,325,847 16,161,626 28,515,834
Trimmed reads 16,112,769
(99.38%)
13,499,180
(99.29%)
17,101,122
(99.33%)
25,093,371
(99.08%)
16,034,860
(99.21%)
28,280,300
(99.17%)
Reads in analysis 15,456,133
(95.33%)
12,732,995
(93.65%)
16,564,900
(96.22%)
24,291,441
(95.91%)
15,173,571
(93.88%)
26,665,506
(93.51%)
Genome/Library mapping
Unique genome mapped reads 83,673
(83.21%)
94,716
(83.32%)
129,731
(85.26%)
219,742
(81.06%)
176,766
(85.44%)
256,859
(82.18%)
Genome mapped reads 14,685,047
(95.01%)
11,757,300
(92.34%)
14,969,574
(90.37%)
22,681,622
(93.37%)
13,734,766
(90.52%)
24,321,990
(91.21%)
MiR profiling results
Reads mapped to miRbase hairpins 5498
(0.09%)
5509
(0.13%)
6896
(0.16%)
6232
(0.21%)
4500
(0.26%)
13,042
(0.30%)
Detected hairpin miR 610
(31.82%)
567
(29.58%)
562
(29.32%)
574
(29.94%)
486
(25.35%)
644
(33.59%)
Reads mapped to mature miR 6,042,081
(96.83%)
3,997,760
(95.42%)
3,812,542
(89.64%)
2,643,351
(88.88%)
1,420,368
(83.35%)
3,586,353
(81.90%)
Detected mature miRNA 916
(34.49%)
842
(31.70%)
834
(31.40%)
825
(31.06%)
711
(26.77%)
939
(35.35%)

RC, reads count of the mature sequence (canonical sequence and all isomiRs). MiRNA reference miRBase, version 22 (http://www.mirbase.org). Hairpins, 1917 and mature, 2656.

The abundance of miRNAs in stored PC bags described in Table 1, shows an increase in the number of reads until the third day of storage (PC-3), followed by a decrease in PCs on the fourth (p = 0.023) and the fifth (p = 8.9E-08) days, with an increase in the median expression, exceeding the average of normalized expression of 4.8 CPM (Figure 1A). As a direct consequence of two more days of storage, the PC on the seventh day (PC-7) presented the largest number of reads and 939 miRNAs, which represented an increase of 2.5% observed after seven days of blood collection, confirmed by the decrease in the median. These results confirm that storage for more than five days in a blood bank causes a decrease in the levels of miRNA expression in the PC.

Figure 1.

Figure 1

(A) Average levels of normalized expression in Log2 counting per million reads (CPM) of miRNA in platelet concentrates (PCs). The average expression was 4.8 CPM. Boxplot is designed from the 75th to the 25th percentile. The vertical lines above and below the box define the maximum and minimum values and the dots indicate outliers, the horizontal line inside the box represents the median value. Kruskal–Wallis test (p-value <0.001) was applied to compare the means between the six groups (** p < 0.01, **** p < 0.0001); (B) The heatmap shows an expression profile defined by the most abundant miRNA families in all PCs. Z-score was the metric applied to infer the best clustering between miRNA families. Gradients with a red tendency represent families of miRNAs with a lower Z-score and gradients with a blue tendency with a higher Z-score; (CH) Donut chart shows the ranking of miRNA family positions on all PCs. PC, platelet concentrate.

Then, we analyzed the miRNA annotation files obtained with sRNAbench. We found a group of very abundant miRNA families that were shown in the unsupervised cluster analysis, represented by mir-486, let-7, mir-25, and mir-191. A second group of families are also grouped, whose members are represented by mir-423, mir-320, mir-181, mir-103, mir-10, mir-127, mir-221, mir-22, mir-28 and mir-26 (Figure 1B).

We provided a panoramic view of the distribution of these miRNA families in all PCs (Figure 1C–H), where we could see the predominance of the mir-486, let-7, mir-25, and mir-191 families, except for on PC-3 which presented the most abundant mir-423. From this information, we also identified the top-20 miRNAs most expressed. Table 2 shows the detailed information on the precursor (pre-microRNA) and the mature miRNAs identified in this study from the annotation files. It shows a decrease in the level of expression of these miRNAs until PC-5 and an increase after two days on PC-7. In Supplementary Materials File S1, we present detailed information on several canonical miRNAs, with specimens that had their functions elucidated in platelets, in addition to a wide variety of miRNAs that have not been described in the literature.

Table 2.

The top-20 miRNAs most expressed in platelet concentrates.

(1) Pre-microRNA (2) Mature microRNA
Gene Family Coordinate String Pre-microRNA Unique Reads Read Count (RC) RPM (Lib) RPM (Total) Mature microRNA Sequence: miR -5p/-3p Arms Unique Reads Read Count (RC) RPM (Lib) RPM (Total)
PC-1 (SRX716593) mir-486 8:hsa;mir-486-2,41660444,41660465,+ mir-486-2 1292 3,255,194 538,264 221,667 miR-486-5p 5p-UCCUGUACUGAGCCGCCCCGAG 1189 3,253,869 538,534 221,577
mir-191 3:hsa;mir-191,49020633,49020655,- mir-191 335 639,518 105,748 43,549 miR-191-5p 5p-CAACGGAAUCCCAAAAGCAGCUG 318 639,420 105,828 43,542
let-7 12:hsa;let-7i,62603691,62603712,+ let-7i 205 243,758 40,307 16,599 let-7i-5p 5p-UGAGGUAGUAGUUUGUGCUGUU 194 243,687 40,332 16,594
mir-25 13:hsa;mir-92a-1,91351361,91351382,+ mir-92a-1 510 220,091 36,393 14,987 miR-92a-3p 3p-UAUUGCACUUGUCCCGGCCUGU 497 220,034 36,417 14,984
mir-181 1:hsa;mir-181a-1,198859067,198859089,- mir-181a-1 264 161,979 26,784 11,030 miR-181a-5p 5p-AACAUUCAACGCUGUCGGUGAGU 254 161,722 26,766 11,013
let-7 9:hsa;let-7a-1,94175962,94175983,+ let-7a-1 175 159,936 26,446 10,891 let-7a-5p 5p-UGAGGUAGUAGGUUGUAUAGUU 173 159,928 26,469 10,891
let-7 22:hsa;let-7b,46113691,46113712,+ let-7b 304 121,975 20,169 8306 let-7b-5p 5p-UGAGGUAGUAGGUUGUGUGGUU 286 121,845 20,166 8297
mir-320 8:hsa;mir-320a,22245007,22245028,- mir-320a 578 86,702 14,337 5904 miR-320a-3p 3p-AAAAGCUGGGUUGAGAGGGCGA 561 86,637 14,339 5900
mir-127 14:hsa;mir-127,100883035,100883056,+ mir-127 320 84,993 14,054 5788 miR-127-3p 3p-UCGGAUCCGUCUGAGCUUGGCU 283 84,810 14,037 5775
mir-103 20:hsa;mir-103a-2,3917541,3917563,+ mir-103a-2 188 58,511 9675 3984 miR-103a-3p 3p-AGCAGCAUUGUACAGGGCUAUGA 181 58,469 9677 3982
mir-26 12:hsa;mir-26a-2,57824622,57824643,- mir-26a-2 132 52,776 8727 3594 miR-26a-5p 5p-UUCAAGUAAUCCAGGAUAGGCU 131 52,774 8734 3594
mir-28 8:hsa;mir-151a,140732610,140732630,- mir-151a 274 63,281 10,464 4309 miR-151a-3p 3p-CUAGACUGAAGCUCCUUGAGG 221 51,561 8534 3511
mir-423 17:hsa;mir-423,30117095,30117117,+ mir-423 433 66,631 11,018 4537 miR-423-5p 5p-UGAGGGGCAGAGAGCGAGACUUU 213 51,007 8442 3473
let-7 3:hsa;let-7g,52268282,52268303,- let-7g 114 48,462 8013 3300 let-7g-5p 5p-UGAGGUAGUAGUUUGUACAGUU 110 48,451 8019 3299
mir-22 17:hsa;mir-22,1713955,1713976,- mir-22 88 48,146 7961 3279 miR-22-3p 3p-AAGCUGCCAGUUGAAGAACUGU 81 48,015 7947 3270
mir-10 X:hsa;mir-221,45746221,45746243,- mir-221 190 45,199 7474 3078 miR-221-3p 3p-AGCUACAUUGUCUGCUGGGUUUC 168 44,952 7440 3061
mir-221 X:hsa;let-7f-2,53557199,53557220,- let-7f-2 95 38,034 6289 2590 let-7f-5p 5p-UGAGGUAGUAGAUUGUAUAGUU 94 38,032 6295 2590
let-7 9:hsa;let-7d,94178841,94178862,+ let-7d 125 29,204 4829 1989 let-7d-5p 5p-AGAGGUAGUAGGUUGCAUAGUU 88 25,688 4252 1749
let-7 3:hsa;mir-28,188688834,188688855,+ mir-28 154 23,667 3913 1612 miR-28-3p 3p-AAGGAGCUCACAGUCUAUUGAG 134 23,057 3816 1570
mir-423 17:hsa;mir-423,30117131,30117153,+ mir-423 433 66,631 11,018 4537 miR-423-3p 3p-AGCUCGGUCUGAGGCCCCUCAGU 216 15,610 2584 1063
PC-2 (SRX716594) 6209 5,514,688 911,884 375,531 5392 5,429,568 898,626 369,734
mir-486 8:hsa;mir-486-2,41660444,41660465,+ mir-486-2 1048 1,706,986 426,398 145,185 miR-486-5p 5p-UCCUGUACUGAGCCGCCCCGAG 995 1,705,861 426,704 145,090
mir-191 3:hsa;mir-191,49020633,49020655,- mir-191 264 412698 103,090 35,101 miR-191-5p 5p-CAACGGAAUCCCAAAAGCAGCUG 251 412,617 103,212 35,095
let-7 12:hsa;let-7i,62603691,62603712,+ let-7i 206 216,034 53,964 18,374 let-7i-5p 5p-UGAGGUAGUAGUUUGUGCUGUU 195 215,993 54,029 18,371
let-7 9:hsa;let-7a-1,94175962,94175983,+ let-7a-1 191 204,590 51,106 17,401 let-7a-5p 5p-UGAGGUAGUAGGUUGUAUAGUU 186 204,568 51,171 17,399
mir-25 13:hsa;mir-92a-1,91351361,91351382,+ mir-92a-1 476 193,534 48,344 16,461 miR-92a-3p 3p-UAUUGCACUUGUCCCGGCCUGU 465 193,492 48,400 16,457
let-7 22:hsa;let-7b,46113691,46113712,+ let-7b 305 115,041 28,737 9785 let-7b-5p 5p-UGAGGUAGUAGGUUGUGUGGUU 286 114,919 28,746 9774
mir-181 1:hsa;mir-181a-1,198859067,198859089,- mir-181a-1 227 112,339 28,062 9555 miR-181a-5p 5p-AACAUUCAACGCUGUCGGUGAGU 220 112,168 28,058 9540
mir-127 14:hsa;mir-127,100883035,100883056,+ mir-127 358 100,453 25,093 8544 miR-127-3p 3p-UCGGAUCCGUCUGAGCUUGGCU 325 100,285 25,085 8530
mir-320 8:hsa;mir-320a,22245007,22245028,- mir-320a 563 77,271 19,302 6572 miR-320a-3p 3p-AAAAGCUGGGUUGAGAGGGCGA 549 77,217 19,315 6568
let-7 3:hsa;let-7g,52268282,52268303,- let-7g 114 61,357 15,327 5219 let-7g-5p 5p-UGAGGUAGUAGUUUGUACAGUU 114 61,357 15,348 5219
mir-423 17:hsa;mir-423,30117095,30117117,+ mir-423 429 68,554 17,125 5831 miR-423-5p 5p-UGAGGGGCAGAGAGCGAGACUUU 230 52,321 13,088 4450
mir-221 X:hsa;let-7f-2,53557199,53557220,- let-7f-2 104 44,961 11,231 3824 let-7f-5p 5p-UGAGGUAGUAGAUUGUAUAGUU 103 44,959 11,246 3824
mir-103 20:hsa;mir-103a-2,3917541,3917563,+ mir-103a-2 173 43,831 10,949 3728 miR-103a-3p 3p-AGCAGCAUUGUACAGGGCUAUGA 169 43,806 10,958 3726
mir-10 X:hsa;mir-221,45746221,45746243,- mir-221 165 42,299 10,566 3598 miR-221-3p 3p-AGCUACAUUGUCUGCUGGGUUUC 155 42,203 10,557 3590
mir-22 17:hsa;mir-22,1713955,1713976,- mir-22 80 39,426 9848 3353 miR-22-3p 3p-AAGCUGCCAGUUGAAGAACUGU 76 39,365 9847 3348
mir-26 12:hsa;mir-26a-2,57824622,57824643,- mir-26a-2 102 36,592 9141 3112 miR-26a-5p 5p-UUCAAGUAAUCCAGGAUAGGCU 102 36,592 9153 3112
mir-28 8:hsa;mir-151a,140732610,140732630,- mir-151a 223 42,658 10,656 3628 miR-151a-3p 3p-CUAGACUGAAGCUCCUUGAGG 173 33,633 8413 2861
let-7 9:hsa;let-7d,94178841,94178862,+ let-7d 128 33,592 8391 2857 let-7d-5p 5p-AGAGGUAGUAGGUUGCAUAGUU 88 28,835 7213 2453
mir-423 17:hsa;mir-423,30117131,30117153,+ mir-423 429 68,554 17,125 5831 miR-423-3p 3p-AGCUCGGUCUGAGGCCCCUCAGU 194 16,218 4057 1379
let-7 3:hsa;mir-28,188688834,188688855,+ mir-28 125 16,257 4061 1383 miR-28-3p 3p-AAGGAGCUCACAGUCUAUUGAG 112 15,755 3941 1340
PC-3 (SRX716595) 5710 3,637,027 908,514 309,342 4988 3,552,164 888,539 302,124
mir-486 8:hsa;mir-486-2,41660444,41660465,+ mir-486-2 370 120,353 31,511 8040 miR-486-5p 5p-UCCUGUACUGAGCCGCCCCGAG 982 1,894,623 496,945 126,565
mir-191 3:hsa;mir-191,49020633,49020655,- mir-191 260 374,338 98,009 25,007 miR-191-5p 5p-CAACGGAAUCCCAAAAGCAGCUG 249 374,253 98,164 25,001
let-7 12:hsa;let-7i,62603691,62603712,+ let-7i 186 221,365 57,957 14,788 let-7i-5p 5p-UGAGGUAGUAGUUUGUGCUGUU 180 221,341 58,056 14,786
mir-25 13:hsa;mir-92a-1,91351361,91351382,+ mir-92a-1 476 193,534 48,344 16,461 miR-92a-3p 3p-UAUUGCACUUGUCCCGGCCUGU 357 120,306 31,555 8037
mir-181 1:hsa;mir-181a-1,198859067,198859089,- mir-181a-1 219 106,232 27,814 7097 miR-181a-5p 5p-AACAUUCAACGCUGUCGGUGAGU 212 106,081 27,824 7086
let-7 9:hsa;let-7a-1,94175962,94175983,+ let-7a-1 138 100,930 26,425 6742 let-7a-5p 5p-UGAGGUAGUAGGUUGUAUAGUU 136 100,925 26,472 6742
let-7 22:hsa;let-7b,46113691,46113712,+ let-7b 267 96,496 25,264 6446 let-7b-5p 5p-UGAGGUAGUAGGUUGUGUGGUU 254 96,409 25,287 6440
mir-320 8:hsa;mir-320a,22245007,22245028,- mir-320a 605 94,553 24,756 6316 miR-320a-3p 3p-AAAAGCUGGGUUGAGAGGGCGA 588 94,482 24,782 6312
mir-127 14:hsa;mir-127,100883035,100883056,+ mir-127 348 93,636 24,516 6255 miR-127-3p 3p-UCGGAUCCGUCUGAGCUUGGCU 320 93,488 24,521 6245
mir-423 17:hsa;mir-423,30117095,30117117,+ mir-423 1053 1,895,916 496,386 126,651 miR-423-5p 5p-UGAGGGGCAGAGAGCGAGACUUU 217 57,556 15,096 3845
mir-10 X:hsa;mir-221,45746221,45746243,- mir-221 173 41,049 10,747 2742 miR-221-3p 3p-AGCUACAUUGUCUGCUGGGUUUC 161 40,980 10,749 2738
mir-103 20:hsa;mir-103a-2,3917541,3917563,+ mir-103a-2 162 40,194 10,524 2685 miR-103a-3p 3p-AGCAGCAUUGUACAGGGCUAUGA 156 40,167 10,535 2683
let-7 3:hsa;let-7g,52268282,52268303,- let-7g 89 37,080 9708 2477 let-7g-5p 5p-UGAGGUAGUAGUUUGUACAGUU 88 37,076 9725 2477
mir-22 17:hsa;mir-22,1713955,1713976,- mir-22 72 31,563 8264 2108 miR-22-3p 3p-AAGCUGCCAGUUGAAGAACUGU 67 31,518 8267 2105
mir-26 12:hsa;mir-26a-2,57824622,57824643,- mir-26a-2 85 24,891 6517 1663 miR-26a-5p 5p-UUCAAGUAAUCCAGGAUAGGCU 85 24,891 6529 1663
mir-28 8:hsa;mir-151a,140732610,140732630,- mir-151a 184 27,165 7112 1815 miR-151a-3p 3p-CUAGACUGAAGCUCCUUGAGG 142 23,095 6058 1543
mir-221 X:hsa;let-7f-2,53557199,53557220,- let-7f-2 59 21,314 5580 1424 let-7f-5p 5p-UGAGGUAGUAGAUUGUAUAGUU 59 21,314 5591 1424
mir-423 17:hsa;mir-423,30117131,30117153,+ mir-423 426 74,297 19,452 4963 miR-423-3p 3p-AGCUCGGUCUGAGGCCCCUCAGU 206 16,734 4389 1118
let-7 9:hsa;let-7d,94178841,94178862,+ let-7d 107 20,065 5253 1340 let-7d-5p 5p-AGAGGUAGUAGGUUGCAUAGUU 69 16,136 4232 1078
let-7 3:hsa;mir-28,188688834,188688855,+ mir-28 105 11,734 3072 784 miR-28-3p 3p-AAGGAGCUCACAGUCUAUUGAG 95 11,468 3008 766
PC-4 (SRX716596) 5384 3,626,705 947,212 245,804 4623 3,422,843 897,785 228,653
mir-486 8:hsa;mir-486-2,41660444,41660465,+ mir-486-2 935 894,301 337,525 39,428 miR-486-5p 5p-UCCUGUACUGAGCCGCCCCGAG 873 893,294 337,940 39,384
mir-191 3:hsa;mir-191,49020633,49020655,- mir-191 241 231,963 87,547 10,227 miR-191-5p 5p-CAACGGAAUCCCAAAAGCAGCUG 231 231,904 87,731 10,224
mir-25 13:hsa;mir-92a-1,91351361,91351382,+ mir-92a-1 564 229,695 86,691 10,127 miR-92a-3p 3p-UAUUGCACUUGUCCCGGCCUGU 551 229,650 86,878 10,125
let-7 22:hsa;let-7b,46113691,46113712,+ let-7b 472 190,538 71,912 8401 let-7b-5p 5p-UGAGGUAGUAGGUUGUGUGGUU 403 190,076 71,907 8380
let-7 9:hsa;let-7a-1,94175962,94175983,+ let-7a-1 201 160,740 60,666 7087 let-7a-5p 5p-UGAGGUAGUAGGUUGUAUAGUU 190 160,652 60,776 7083
let-7 12:hsa;let-7i,62603691,62603712,+ let-7i 193 127,164 47,994 5606 let-7i-5p 5p-UGAGGUAGUAGUUUGUGCUGUU 182 127,135 48,096 5605
mir-181 1:hsa;mir-181a-1,198859067,198859089,- mir-181a-1 215 89,739 33,869 3956 miR-181a-5p 5p-AACAUUCAACGCUGUCGGUGAGU 200 89,565 33,883 3949
mir-320 8:hsa;mir-320a,22245007,22245028,- mir-320a 686 77,769 29,351 3429 miR-320a-3p 3p-AAAAGCUGGGUUGAGAGGGCGA 653 77,613 29,362 3422
mir-423 17:hsa;mir-423,30117095,30117117,+ mir-423 440 71,225 26,882 3140 miR-423-5p 5p-UGAGGGGCAGAGAGCGAGACUUU 265 56,960 21,548 2511
mir-26 12:hsa;mir-26a-2,57824622,57824643,- mir-26a-2 118 45,261 17,082 1995 miR-26a-5p 5p-UUCAAGUAAUCCAGGAUAGGCU 118 45,261 17,123 1995
let-7 3:hsa;let-7g,52268282,52268303,- let-7g 104 38,106 14,382 1680 let-7g-5p 5p-UGAGGUAGUAGUUUGUACAGUU 101 38,097 14,412 1680
mir-127 14:hsa;mir-127,100883035,100883056,+ mir-127 236 32,655 12,325 1440 miR-127-3p 3p-UCGGAUCCGUCUGAGCUUGGCU 210 32556 12,316 1435
mir-28 8:hsa;mir-151a,140732610,140732630,- mir-151a 214 32,928 12,428 1452 miR-151a-3p 3p-CUAGACUGAAGCUCCUUGAGG 171 26,728 10,111 1178
let-7 9:hsa;let-7d,94178841,94178862,+ let-7d 135 30,214 11,403 1332 let-7d-5p 5p-AGAGGUAGUAGGUUGCAUAGUU 82 23,494 8888 1036
let-7 3:hsa;mir-28,188688834,188688855,+ mir-28 136 22,513 8497 993 miR-28-3p 3p-AAGGAGCUCACAGUCUAUUGAG 125 22,352 8456 985
mir-221 X:hsa;let-7f-2,53557199,53557220,- let-7f-2 74 21,246 8019 937 let-7f-5p 5p-UGAGGUAGUAGAUUGUAUAGUU 72 21,241 8036 936
mir-10 X:hsa;mir-221,45746221,45746243,- mir-221 112 18,302 6908 807 miR-221-3p 3p-AGCUACAUUGUCUGCUGGGUUUC 105 18,262 6909 805
mir-22 17:hsa;mir-22,1713955,1713976,- mir-22 52 16,322 6160 720 miR-22-3p 3p-AAGCUGCCAGUUGAAGAACUGU 49 16,306 6169 719
mir-423 17:hsa;mir-423,30117131,30117153,+ mir-423 440 71,225 26,882 3140 miR-423-3p 3p-AGCUCGGUCUGAGGCCCCUCAGU 166 14,240 5387 628
mir-103 20:hsa;mir-103a-2,3917541,3917563,+ mir-103a-2 109 8830 3333 389 miR-103a-3p 3p-AGCAGCAUUGUACAGGGCUAUGA 108 8827 3339 389
PC-5 (SRX716597) 5677 2,410,736 909,855 106,286 4855 2,324,213 879,268 102,471
mir-486 8:hsa;mir-486-2,41660444,41660465,+ mir-486-2 683 615,100 431,689 44,784 miR-486-5p 5p-UCCUGUACUGAGCCGCCCCGAG 652 614,560 432,677 44,745
mir-191 3:hsa;mir-191,49020633,49020655,- mir-191 157 104,250 73,165 7590 miR-191-5p 5p-CAACGGAAUCCCAAAAGCAGCUG 152 104,216 73,373 7588
let-7 22:hsa;let-7b,46113691,46113712,+ let-7b 249 75,462 52,961 5494 let-7b-5p 5p-UGAGGUAGUAGGUUGUGUGGUU 230 75,389 53,077 5489
mir-25 13:hsa;mir-92a-1,91351361,91351382,+ mir-92a-1 311 75,403 52,919 5490 miR-92a-3p 3p-UAUUGCACUUGUCCCGGCCUGU 305 75,383 53,073 5488
let-7 9:hsa;let-7a-1,94175962,94175983,+ let-7a-1 123 68,853 48,322 5013 let-7a-5p 5p-UGAGGUAGUAGGUUGUAUAGUU 120 68,845 48,470 5012
let-7 12:hsa;let-7i,62603691,62603712,+ let-7i 117 54,798 38,458 3990 let-7i-5p 5p-UGAGGUAGUAGUUUGUGCUGUU 113 54,789 38,574 3989
mir-181 1:hsa;mir-181a-1,198859067,198859089,- mir-181a-1 157 51,930 36,445 3781 miR-181a-5p 5p-AACAUUCAACGCUGUCGGUGAGU 147 51,833 36,493 3774
mir-423 17:hsa;mir-423,30117131,30117153,+ mir-423 282 35,167 24,681 2560 miR-423-3p 3p-AGCUCGGUCUGAGGCCCCUCAGU 130 11,232 7908 818
mir-423 17:hsa;mir-423,30117095,30117117,+ mir-423 282 35,167 24,681 2560 miR-423-5p 5p-UGAGGGGCAGAGAGCGAGACUUU 151 23,930 16,848 1742
mir-320 8:hsa;mir-320a,22245007,22245028,- mir-320a 377 34,546 24,245 2515 miR-320a-3p 3p-AAAAGCUGGGUUGAGAGGGCGA 367 34,507 24,294 2512
mir-22 17:hsa;mir-22,1713955,1713976,- mir-22 51 21,777 15,284 1586 miR-22-3p 3p-AAGCUGCCAGUUGAAGAACUGU 68 10,244 7212 746
mir-26 12:hsa;mir-26a-2,57824622,57824643,- mir-26a-2 77 20,298 14,246 1478 miR-26a-5p 5p-UUCAAGUAAUCCAGGAUAGGCU 76 20,295 14,289 1478
mir-221 X:hsa;let-7f-2,53557199,53557220,- let-7f-2 64 18,956 13,304 1380 let-7f-5p 5p-UGAGGUAGUAGAUUGUAUAGUU 64 18,956 13,346 1380
let-7 3:hsa;let-7g,52268282,52268303,- let-7g 56 15,713 11,028 1144 let-7g-5p 5p-UGAGGUAGUAGUUUGUACAGUU 54 15,709 11,060 1144
mir-28 8:hsa;mir-151a,140732610,140732630,- mir-151a 139 13,978 9810 1018 miR-151a-3p 3p-CUAGACUGAAGCUCCUUGAGG 109 10,663 7507 776
mir-127 14:hsa;mir-127,100883035,100883056,+ mir-127 135 13,017 9136 948 miR-127-3p 3p-UCGGAUCCGUCUGAGCUUGGCU 126 12,990 9146 946
let-7 9:hsa;let-7d,94178841,94178862,+ let-7d 75 11,189 7853 815 let-7d-5p 5p-AGAGGUAGUAGGUUGCAUAGUU 51 9603 6761 699
mir-10 X:hsa;mir-221,45746221,45746243,- mir-221 75 10,284 7218 749 miR-221-3p 3p-AGCUACAUUGUCUGCUGGGUUUC 47 21,761 15,321 1584
mir-103 20:hsa;mir-103a-2,3917541,3917563,+ mir-103a-2 88 9053 6354 659 miR-103a-3p 3p-AGCAGCAUUGUACAGGGCUAUGA 86 9049 6371 659
let-7 3:hsa;mir-28,188688834,188688855,+ mir-28 82 6351 4457 462 miR-28-3p 3p-AAGGAGCUCACAGUCUAUUGAG 73 6095 4291 444
PC-7 (SRX716598) 3580 1,291,292 906,254 94016 3121 1,250,049 880,088 91,013
mir-486 8:hsa;mir-486-2,41660444,41660465,+ mir-486-2 1130 1,350,603 375,231 55,530 miR-486-5p 5p-UCCUGUACUGAGCCGCCCCGAG 1071 1,349,469 376,279 55,483
mir-191 3:hsa;mir-191,49020633,49020655,- mir-191 277 267,823 74,408 11,012 miR-191-5p 5p-CAACGGAAUCCCAAAAGCAGCUG 266 267,756 746,60 11,009
let-7 22:hsa;let-7b,46113691,46113712,+ let-7b 481 257,858 71,639 10,602 let-7b-5p 5p-UGAGGUAGUAGGUUGUGUGGUU 439 257,625 71,835 10,592
mir-25 13:hsa;mir-92a-1,91351361,91351382,+ mir-92a-1 589 243,120 67,545 9996 miR-92a-3p 3p-UAUUGCACUUGUCCCGGCCUGU 574 243,075 67,778 9994
let-7 12:hsa;let-7i,62603691,62603712,+ let-7i 222 194,147 53,939 7982 let-7i-5p 5p-UGAGGUAGUAGUUUGUGCUGUU 214 194,099 54,122 7980
let-7 9:hsa;let-7a-1,94175962,94175983,+ let-7a-1 206 182,459 50,692 7502 let-7a-5p 5p-UGAGGUAGUAGGUUGUAUAGUU 197 182,420 50,865 7500
mir-181 1:hsa;mir-181a-1,198859067,198859089,- mir-181a-1 253 108,155 30,048 4447 miR-181a-5p 5p-AACAUUCAACGCUGUCGGUGAGU 244 107,985 30,110 4440
mir-320 8:hsa;mir-320a,22245007,22245028,- mir-320a 813 106,945 29,712 4397 miR-320a-3p 3p-AAAAGCUGGGUUGAGAGGGCGA 780 106,785 29,775 4390
mir-423 17:hsa;mir-423,30117095,30117117,+ mir-423 492 90,138 25,043 3706 miR-423-5p 5p-UGAGGGGCAGAGAGCGAGACUUU 267 65,916 18,380 2710
let-7 3:hsa;let-7g,52268282,52268303,- let-7g 104 50,033 13,900 2057 let-7g-5p 5p-UGAGGUAGUAGUUUGUACAGUU 102 50,027 13,949 2057
mir-22 17:hsa;mir-22,1713955,1713976,- mir-22 81 45,147 12,543 1856 miR-22-3p 3p-AAGCUGCCAGUUGAAGAACUGU 78 45,115 12,580 1855
mir-26 12:hsa;mir-26a-2,57824622,57824643,- mir-26a-2 135 44,947 12,487 1848 miR-26a-5p 5p-UUCAAGUAAUCCAGGAUAGGCU 134 44,945 12,532 1848
mir-127 14:hsa;mir-127,100883035,100883056,+ mir-127 299 40,887 11,359 1681 miR-127-3p 3p-UCGGAUCCGUCUGAGCUUGGCU 276 40,818 11,381 1678
mir-28 8:hsa;mir-151a,140732610,140732630,- mir-151a 279 46,226 12,843 1901 miR-151a-3p 3p-CUAGACUGAAGCUCCUUGAGG 221 36,268 10,113 1491
mir-221 X:hsa;let-7f-2,53557199,53557220,- let-7f-2 96 31,868 8854 1310 let-7f-5p 5p-UGAGGUAGUAGAUUGUAUAGUU 95 31,865 8885 1310
mir-10 X:hsa;mir-221,45746221,45746243,- mir-221 178 27,407 7614 1127 miR-221-3p 3p-AGCUACAUUGUCUGCUGGGUUUC 169 27,340 7623 1124
let-7 9:hsa;let-7d,94178841,94178862,+ let-7d 159 35,482 9858 1459 let-7d-5p 5p-AGAGGUAGUAGGUUGCAUAGUU 104 26,539 7400 1091
mir-423 17:hsa;mir-423,30117131,30117153,+ mir-423 492 90,138 25,043 3706 miR-423-3p 3p-AGCUCGGUCUGAGGCCCCUCAGU 221 24,211 6751 995
let-7 3:hsa;mir-28,188688834,188688855,+ mir-28 138 18,683 5191 768 miR-28-3p 3p-AAGGAGCUCACAGUCUAUUGAG 123 18,324 5109 753
mir-103 20:hsa;mir-103a-2,3917541,3917563,+ mir-103a-2 163 16,403 4557 674 miR-103a-3p 3p-AGCAGCAUUGUACAGGGCUAUGA 159 16,386 4569 674
6587 3,248,469 902,504 13,3561 5734 3,136,968 874,696 128,977

Items in the main columns of the table: gene family, coordinate string, pre-microRNA. UR, number of unique reads; RC, read count; RPM (lib), the read per million normalized by the total number of reads mapped to the library to a known microRNA; RPM (total), the reads per million normalized by the total number of genome mapped reads (genome mode) or the total number of reads in the analysis (sequence library mode); mature microRNAs sequence, miR 5p-/3p-arms, arm sequence as defined by the miRBase annotation. The order of classification of miRNAs is based on the RC.

3.2. Measurement of microRNA Expression in PC

After analyzing the miRNA expression files generated with sRNAbench, we identified the top-20 miRNAs most expressed in the PC, represented by the following members: miR-486-5p, miR-191-5p, let-7i-5p, miR-92a-3p, miR-181a-5p, let-7a-5p, let-7b-5p, miR-320a-3p, miR-127-3p, miR-103a-3p, miR-26a-5p, miR-151a-3p, miR-423-5p, let-7g-5p, miR-22-3p, miR-221-3p, let-7f-5p, let-7d-5p, miR-28-3p, and miR-423-3p (Table 2). Considering those 20 miRNAs most expressed that were described, we found that they are part of a family of the 14 most abundant miRNAs in platelets, in which some families present more than one mature miRNA, such as let-7 and mir-423.

In all PCs, high levels of expression of miR-486-5p and miR-191-5p were identified, let-7i-5p being the third most expressed miRNA until PC-3, followed by miR-92a-3p, miR-181a-5p, and the other miRNAs that also occupied prominent positions listed in Table 2. We show the ranking of miRNAs with the normalized expression on the Log2 CPM scale in two separate groups in the graphs depicted in Figure 2A,B.

Figure 2.

Figure 2

Different measures of expression level in PCs (A) and (B) with the normalized expression level in Log2 (CPM) of the 20 miRNAs most expressed. The boxplot is designed from the 75th to the 25th percentile. The vertical lines above and below the box define the maximum and minimum values and the dots indicate outliers, the horizontal line inside the box represents the median value. The Kruskal–Wallis test p-value < 0.001, in all cases was applied to compare the means among the miRNAs expressed in all PCs (** p < 0.01 and *** p = 0.001). Two groups of miRNAs were established to compare the relative expression by the analytical method previously mentioned to evaluate the PC bags.

The first group is represented by (miR-486-5p, miR-191-5p, miR-320a-3p, miR-181a-5p, let-7i-5p, let-7b-5p, let-7a-5p, and miR-92a-3p) and these miRNAs showed a range of expression between 16 and 20 CPM (Figure 2A). Whereas the second group (miR-127-3p, miR-423-5p, miR-26a-5p, let-7g-5p, miR-423-3p, miR-28-3p, let-7d-5p, miR-103a-3p, miR-221-3p, miR-151a-3p, let-7f-5p, and miR-22-3p) varied with expression values above 12.5, approaching 17.5 CPM (Figure 2B).

These two groups of miRNAs had their levels of expression analyzed by the analytical method which compares the relative expression of miRNAs identified by Pontes et al. In a PC bag we can test the following:

  • i.

    Any of the following miRNAs (miR-127-3p, miR-423-5p, miR-26a-5p, let-7g-5p, miR-423-3p, miR-28-3p, let-7d-5p, miR-103a-3p, miR-221-3p, miR-151a-3p, let-7f-5p, and miR-22-3p) that have an expression level <80% in relation to one of the following (miR-486-5p, miR-191-5p, miR-320a-3p, miR-181a-5p, let-7i-5p, let-7b-5p, let-7a-5p, or miR-92a-3p), means that there is storage lesion and immediate blockage of the bag that can be tested at any time.

  • ii.

    If in a PC bag the expression levels of (miR-127-3p, miR-423-5p, miR-26a-5p, let-7g-5p, miR-423-3p, miR-28-3p, let-7d-5p, miR-103a-3p, miR-221-3p, miR-151a-3p, let-7f-5p, and miR-22-3p) ≥80 in relation to one of the following (miR-486 -5p, miR-191-5p, miR-320a-3p, miR-181a-5p, let-7i-5p, let-7b-5p, let-7a-5p, or miR-92a-3p). It is considered that the PC bag can be used for transfusion, as there are no storage lesions.

From the 20 most expressed miRNAs on the PCs, we selected six, i.e., miR-486-5p, miR-92a-3p, miR-103a-3p, miR-151a-3p, miR-181a-5p, and miR-221-3p for qPCR validation on 100 PC units from 500 healthy donors (Figure 3). These miRNAs were chosen among the 20 most expressed RNAs according to the following criteria: have been expressed in all PCs and have not been described in studies of platelet storage lesions. Relative quantification confirmed the results obtained with sRNA-Seq.

Figure 3.

Figure 3

Relative mean expression of miRNAs (quantitative PCR (qPCR) analysis). The average expression of miR-486-5p, miR-92a-3p, miR-103a-3p, miR-151a-3p, miR-181a-5p, and miR-221-3p decreased from PC-4 to PC-5 and increased only on PC-7. ANOVA was applied in multiple comparison tests to estimate the significance of the relative mean of miRNAs in 100 PC units. (ns, not significant, * p < 0.05, ** p < 0.01, *** p = 0.001, **** p < 0.0001). In all graphs, the X-axis represents the storage time of the PCs, and the Y-axis represents the 100 PC units.

Our results show that miR-486-5p, miR-92a-3p, miR-103a-3p, miR-151a-3p, miR-181a-5p, and miR-221-3p decrease from the fourth to the fifth day of PC storage (Figure 3). We compared the average expression of these miRNAs in 100 units of PC on the fourth day (PC-4), confirming that the storage time caused the decrease of these miRNAs, in a much more accentuated way for miR-486-5p more expressed in the sRNA-Seq data (Table 2). All six miRNAs increased their levels of expression on PC-7 (Figure 3).

To understand how the increased of storage time caused changes in miRNAs profiles, we applied computational biology simulation to sRNA-Seq and qPCR data. The results showed miRNAs grouped with similar expression profiles, both for increasing and decreasing expression (Figure 4A,C), and these miRNAs, most likely, could or could not have the same function in PCs with activated platelets. The PCA analysis (Figure 4B,D) was able to identified MiRNAs groups that suffered expression variation caused by the increased storage time, as we observed miR-486-5p, miR-92a-3p, and miR-151a-3p at extreme points of the ellipses and miR-103a-3p, miR-181a-5p, and miR-221-3p (overlapping ellipses). The first principal components (PC1) explained 64.1% of the total miRNA expression variations in the qPCR experiment (Figure 4D).

Figure 4.

Figure 4

Hierarchical cluster (A) and principal component analysis (PCA) (B), generated with sRNA-Seq data. Hierarchical cluster (C) and PCA (D) generated with the validation data by qPCR.

The hierarchical grouping (Figure 4A) shows an expression pattern of 20 miRNAs in six PCs identified with sRNA-Seq. Z-score was the metric applied to infer miRNAs with similar levels of expression. Gradients with a red tendency represent miRNAs with a lower Z-score and gradients with a blue tendency with a higher Z-score. The PCA analysis graph (Figure 4B) shows the grouping of miRNAs with expression level <80% (in red, according to the miR-127-3p expression reference) and miRNAs with expression level 80% on the PC (in blue, according to the miR-320a-3p expression reference). The hierarchical cluster (Figure 4C) and PCA (Figure 4D) identify the associations of miRNAs, miR-486-5p, miR-92a-3p, miR-103a-3p, miR-151a-3p, miR-181a-5p, and miR-221-3p validated with qPCR related to storage lesions. In the PCA analysis graph, ellipses were predicted with a probability of 0.95. The X- and Y-axes show principal component 1 and principal component 2. The first principal component (PC1), explained 94.5% and 64.1% of the total miRNA expression variations in the two experiments, respectively. In both PCAs, the divergences in the first two main components reflect the differences in miRNA profiles with a particularly distinct division between groups.

3.3. IsomiR Quantification

We identified a dominant pattern of expression of mature miRNAs in 5p-arm and 3p-arm, which were investigated systematically. Our results show that non-activated platelets (PC-1), present more than 88.73% of specific miRNAs in 5p-arm and only 11.27% in 3p-arm (Figure 5A). We extended this count across all PCs in an attempt to find significant differences in 5p-arm and 3p-arm expression dominance.

Figure 5.

Figure 5

(A) Expression pattern of miRNAs in 5p-arm and 3p-arm. We showed the amount of crude and (%) count read expressed in the 5p-arm and 3p-arm that are estimated in all PCs; (B) Density of miRNA expression of each PC measured by the log2 of the ratio (5p-arm/3p-arm); (C) Correlogram calculated to highlight the miRNAs that are most correlated with the NTA variants, with an emphasis on miR-486-5p, miR-92a-3p, miR-320a-3p, miR-127-3p, let-7i -5p, let-7b-5p, miR-103a-3p, miR-151a-3p, miR-221-3p, miR-26a-5p, miR-423-3p, and miR-423-5p; (D) Correlogram calculated correlation to highlight the miRNAs that most correlate with the length variants, highlighting miR-486-5p, miR-127-3p, let-7i-5p, miR-103a-3p, miR-423-3p, miR-181a-5p, miR-22-3p, let-7d-5p, miR-423-5p, and let-7g-5p. MiRNAs that have a positive correlation for both variants at the same time were miR-486-5p, miR-127-3p, let-7i-5p, miR-103a-3p, miR-423-3p, and miR-423-5p. In the correlograms, the scales with blue gradient are positively correlated, while the gradients in red color are negatively correlated. Blank scale are miRNAs correlations with p-value >0.01 are considered no significant.

The data indicate that the percentage decrease in miRNA, caused by storage, was 85.75% in 5p-arm and 14.25% in 3p-arm (PC-5) as compared with previous PCs (Figure 5A). We measured the density of miRNA expression by the log2 ratio (5p-arm/3p-arm). A significant difference was found in the level of expression, tens, or hundreds of times greater in the 5p-arm than in the 3p-arm (Figure 5B).

A large number of miRNA different sequences variants were identified in all PCs in a reproducible way (Table 3). In Table 3(1) we identified the total of isomiR expressed in count reads in the form of NTA and length variants. In Table 3(2) we account for the mean and standard deviation of these variants in count reads, detected in the canonical sequence of the 20 miRNAs. The averages were tested with ANOVA (p < 0.001) and were significant. On the one hand, the amount of the NTA(U) variant increased from PC-1 to PC-7 to 67.31%, on the other hand, the NTA(A) variant decreased from PC-1 to PC-7 to 30.42%. The variants NTA(C) and NTA(G) showed less relevant variations in increase and decrease.

Table 3.

Quantification and detection of isomiR variants on platelets concentrates.

(1) Quantification of IsomiR on Platelets Concentrates
Samples NTA
n (%)
length Variants
n (%)
NTA(A) NTA(U) NTA(C) NTA(G) lv3pE lv3pT lv5pE lv5pT mv
PC-1: SRX716593 1,502,312 (37.44%) 2,447,590 (60.99%) 40,885 (1.02%) 22,103 (0.55%) 327,889 (23.06%) 1,003,147 (70.57%) 12,792 (0.90%) 40,465 (2.85%) 37,294 (2.62%)
PC-2: SRX716594 729,738 (32.24%) 1,491,187 (65.88%) 29,352 (1.30%) 13,064 (0.58%) 273,874 (26.53%) 687,827 (66.62%) 11,494 (1.11%) 29,902 (2.90%) 29,309 (2.84%)
PC-3: SRX716595 810,533 (32.93%) 1,608,776 (65.37%) 28,059 (1.14%) 13,731 (0.56%) 228,445 (25.58%) 599,868 (67.17%) 10,425 (1.17%) 27,552 (3.09%) 26,805 (3.0%)
PC-4: SRX716596 408,066 (30.47%) 891,951 (66.59%) 24,271 (1.81%) 15,139 (1.13%) 252,015 (32.18%) 485,983 (62.06%) 8226 (1.05%) 13,027 (1.66%) 23,772 (3.04%)
PC-5: SRX716597 248,172 (31.43%) 524,128 (66.38%) 11,835 (1.50%) 5399 (0.68%) 117,710 (28.07%) 276,958 (66.05%) 4360 (1.04%) 8447 (2.01%) 11,825 (2.82%)
PC-7: SRX716598 563,001 (30.42%) 1,245,683 (67.31%) 28,203 (1.52%) 13,850 (0.75%) 315,489 (30.11%) 666,785 (63.64%) 10,999 (1.05%) 23,665 (2.26%) 30,845 (2.94%)
(2) IsomiR quantification of miRNAs
MicroRNAs NTA(A) NTA(U) NTA(C) NTA(G) lv3pE lv3pT lv5pE lv5pT mv
Mean ± SD Mean ± SD Mean ± SD Mean ± SD Mean ± SD Mean ± SD Mean ± SD Mean ± SD Mean ± SD
miR-486-5p 309,714.33 ± 214,491.01 574,218.67 ± 322,270.07 5408.50 ± 2232.18 3203.00 ± 1596.31 8734.00 ± 6386.92 164,491.33 ± 70,125.67 0.00 ± 0.00 1229.17 ± 695.15 488.50 ± 291.12
miR-92a-3p 24,452.83 ± 11,342.48 53,794.17 ± 24,607.88 1299.67 ± 567.11 441.00 ± 198.83 15,592.33 ± 5685.46 2098.67 ± 1071.13 0.00 ± 0.00 4383.33 ± 2515.53 1046.33 ± 581.30
miR-320a-3p 70.00 ± 26.11 36,580.33 ± 11,751.30 3276.83 ± 1017.55 586.50 ± 196.71 11,801.83 ± 4316.82 4569.67 ± 1424.88 316.33 ± 109.64 601.67 ± 222.68 1153.83 ± 405.98
miR-127-3p 24,75.50 ± 1398.62 23,384.33 ± 14,379.70 528.67 ± 284.26 135.17 ± 68.68 69.67 ± 39.70 2250.83 ± 1379.51 1.00 ± 1.67 23.67 ± 12.20 51.33 ± 30.78
let-7i-5p 5077.67 ± 1715.29 15,656.33 ± 5569.34 244.67 ± 94.76 63.33 ± 27.44 271.33 ± 91.98 13,603.17 ± 6109.05 49.17 ± 30.21 73.00 ± 42.30 3.17 ± 5.45
let-7b-5p 4275.00 ± 2339.25 15,041.50 ± 8794.91 276.67 ± 107.23 1220.33 ± 447.08 42,038.67 ± 23925.81 13,505.17 ± 5057.22 0.33 ± 0.81 27.17 ± 19.67 89.00 ± 74.70
miR-103a-3p 19.00 ± 10.25 6990.67 ± 5086.50 427.00 ± 299.86 83.50 ± 62.05 399.83 ± 304.29 3527.33 ± 2085.80 0.00 ± 0.00 107.33 ± 60.68 16.50 ± 14.39
miR-151a-3p 1053.67 ± 520.25 5477.33 ± 2625.91 1695.17 ± 745.09 12.67 ± 8.35 12,337.17 ± 5300.43 194.83 ± 128.54 1263.83 ± 479.98 18.17 ± 15.14 489.50 ± 191.70
miR-221-3p 255.83 ± 92.34 5208.17 ± 2445.48 39.83 ± 18.62 98.50 ± 43.19 233.67 ± 103.63 8629.50 ± 3483.21 0.83 ± 1.32 31.83 ± 21.29 18.33 ± 11.37
miR-26a-5p 326.67 ± 140.92 2566.17 ± 947.53 202.00 ± 83.77 99.33 ± 64.75 98.00 ± 43.78 814.00 ± 251.09 0.00 ± 0.00 90.00 ± 31.56 3.00 ± 2.44
miR-423-3p 629.83 ± 262.84 2468.17 ± 523.97 42.33 ± 17.09 21.33 ± 6.71 34.50 ± 10.15 1111.50 ± 505.16 1174.50 ± 270.23 91.83 ± 30.45 244.00 ± 96.06
miR-28-3p 3834.83 ± 1724.38 2080.50 ± 861.14 1169.50 ± 506.45 9.83 ± 7.19 313.67 ± 176.53 451.17 ± 194.87 8.83 ± 3.86 88.33 ± 33.26 641.33 ± 309.20
miR-423-5p 1027.50 ± 347.28 1931.33 ± 692.43 246.67 ± 79.94 73.17 ± 28.13 8093.67 ± 2410.61 10,057.67 ± 3071.29 3.50 ± 3.72 56.00 ± 21.75 106.83 ± 42.37
miR-181a-5p 1010.00 ± 364.20 995.00 ± 335.88 64.17 ± 36.45 496.00 ± 211.93 4112.50 ± 2167.39 59,343.00 ± 22,151.37 24.17 ± 9.04 32.17 ± 13.25 147.00 ± 46.51
miR-191-5p 593.00 ± 377.16 354.17 ± 359.66 138.00 ± 61.92 394.33 ± 220.96 18,876.83 ± 8085.89 3657.83 ± 3352.16 0.00 ± 0.00 6858.50 ± 4181.14 688.33 ± 335.25
let-7g-5p 560.33 ± 291.29 102.83 ± 35.91 24.00 ± 13.08 87.17 ± 33.34 1824.00 ± 654.24 3554.83 ± 1964.37 193.67 ± 74.25 4.50 ± 5.35 33.67 ± 16.21
let-7a-5p 1487.17 ± 713.56 34.17 ± 15.19 112.67 ± 37.51 250.83 ± 85.09 13,054.83 ± 4155.43 10,072.00 ± 3754.47 3.83 ± 3.65 54.33 ± 51.65 44.17 ± 18.68
let-7d-5p 251.00 ± 93.41 9.33 ± 6.71 15.83 ± 8.97 45.50 ± 16.02 2268.83 ± 731.15 1409.00 ± 563.21 10.00 ± 4.00 74.83 ± 40.87 18.33 ± 10.23
miR-22-3p 63.00 ± 24.42 6.83 ± 6.17 5.17 ± 1.94 54.83 ± 20.99 60.83 ± 39.65 1100.67 ± 466.98 3.17 ± 2.85 79.83 ± 42.65 1.67 ± 1.50
let-7f-5p 343.50 ± 128.08 1.33 ± 2.42 25.33 ± 9.58 3.50 ± 3.20 1374.67 ± 384.31 2608.00 ± 1280.50 14.00 ± 7.07 16.00 ± 15.33 7.83 ± 5.34

IsomiR types: NTA (non-templated additions), A (adenine addition), C (cytosine addition); U (U/T addition, (U) uracil and (T) thymine); G (guanine addition). NTA(A), number of reads with a non-templated A addition; NTA(U), number of reads with a non-templated U addition; NTA(C), number of reads with a non-templated C addition; NTA(G), number of reads with a non-templated G addition. Length variants: lv3pE, number of reads with 3′ length extension (longer than the canonical sequence); lv3pT, number of reads with 3′ length trimming (shorter than the canonical sequence); lv5pE, number of reads with 5′ length extension (longer than the canonical sequence); lv5pT, number of reads with 5′ length extension (shorter than the canonical sequence); mv, number of reads classified as multiple length variants. All isomiRs are quantified in read count. ANOVA was used to test the means in each group of isomiRs with p-value <0.001 in all groups tested. n (%), number and the percentage value of isomiRs, respectively; SD, standard deviation.

The most abundant length variants were lv3pT which decreased from PC-1 to PC-7 to 63.64%, whereas lv5pE increased from PC-1 to PC-7 to 30.11%. The lv5pE, lv5pT, and mv variants were less abundant. Sequence variants were correlated to miRNAs by calculating the correlation matrix (Figure 5C,D), which highlighted the following miRNAs: miR-486-5p, miR-127-3p, let-7i-5p, miR-103a-3p, miR-423-3p, and miR-423-5p (Table 3). These showed a positive correlation for both variants at the same time. We gathered more detailed information on these variants which is available in Supplementary Materials File S2.

3.4. Functional microRNA-gene Interaction on the PC

The results of the miRNAs target prediction genes showed that the subsets of predicted and validated interactions share 275 (23.3%) of accounted interactions (Figure 6A). The first network of miRNA–gene interaction constructed with file (1), presented 339 nodes and 1070 edges, while the second network constructed with file (2) presented 127 nodes and 560 edges. The final network merged from the first two networks presents 108 nodes and 220 edges (Figure 6B). The network topology presents a central region formed by denser connections with miRNA–gene interactions, ordered by the MCC mainly for let-7d-5p, let-7a-5p, let-7i-5p, let-7b-5p, let-7f-5p, and let-7g-5p, in addition to the YOD1 gene and compositions formed by miR-92a-3p, miR-423-5p and miR-103a-3p.

Figure 6.

Figure 6

(A) Three subsets of data obtained with target prediction with miRWalk generated 67 (5.7%) interactions in file (1) TargetScan + miRDB, 732 (62.1%) of interactions in file (2) TargetScan + miRTarBase and 83 (7%) of interactions in file (3) miRDB + miRTarBase. Both files share 275 (23.3%) interactions at the same time; (B) The network of miRNA–gene interactions built with Cytoscape using the maximal clique centrality (MCC) method that was applied to identify regions of denser connections of miRNA–gene interactions. The nodes are represented by the red, orange, and yellow gradient circles that were ranked by the MCC. The edges are identified by circles in blue; (C) The most enriched GO terms in three functional categories, i.e., molecular function (MF), cell component (CC), and biological process (BP) for the main genes of the network constructed from 275 miRNA–gene interactions; (D) The main KEGG pathways for the functional enrichment of genes in this network were normalized with -Log10 (p-value).

Most of the genes in the network in Figure 6B were enriched in GO, mainly in the categories of molecular function for protein binding (GO: 0005515), cellular component for nucleoplasm (GO: 0005654), and in a biological process for negative regulation of transcription, DNA-templated (GO: 0045892) (Figure 6C). These genes were also enriched with DAVID [39], generating a wide pathway panel with an important functional repertoire for the P53 signaling pathway, described in signs of oxidative stress, including DNA damage, activation of oncogenes, cell cycle arrest, senescence, and apoptosis. Pathways with an impact on cancer, cell cycle and platelet activation, and other pathways directly associated with cellular stimuli, signal transduction, cell signaling, and stress response were predicted (Figure 6D). The results of these analyses are in Supplementary Material file S3.

4. Discussion

Aging is characterized by a functional decline in many physiological systems that can be triggered by environmental and endogenous stress, including the wear on telomeres, genomic instability, epigenetic changes, and loss of proteostasis, favoring cell damage and the progression of physiological aging [43].

Platelets are small anucleated cells that essentially originate from the fragmentation of pseudopods from the megakaryocyte cytoplasmic membrane in the bone marrow [44]. In a healthy person, platelets circulate in the blood for about seven to ten days, and then are removed from circulation and destroyed in the spleen [45,46]. Similarly, this aging also occurs in vitro, wherein blood banks in most countries, blood components widely used and routinely supplied in the form of PCs are discarded after five days of storage [47].

Platelet storage in blood banks causes a decrease in the abundance of miRNAs due to shear stress and platelet activation, being the two main factors responsible for the release of microparticles (MPs) rich in miRNAs [11,12,13]. Studies of this nature have shown a relationship between miRNA profiles with subsequent platelet reactivity, suggesting an important role in post-transcriptional regulation during storage [7,24,48].

In this study, we identified the 20 most expressed miRNAs in PCs stored for seven days with a genomic coverage of 95%. Specifically, in the PC with high-quality platelets (PC-1), we identified a total of 916 miRNAs (Table 1). However, we confirmed a 22.4% decrease in miRNA levels from the first to the fifth day, much more accentuated than the value found in our previous study [20], increasing the number of miRNAs only after seven days of blood collection with a rate of 2.5, which is, most likely, a response to inhibit the translation of proteins induced by stress caused by aging for more than seven days of storage [20]. On the basis of these results, we emphasize that the use of different bioinformatics pipelines to analyze the same sequencing data, generates results that can differ substantially. Whereas, some studies have highlighted the urgent need to ensure that the bioinformatics pipelines used for next-generation sequencing (NGS) analysis, undergo better validation, especially for applications in translational genomic medicine [49].

In our data, we observed the influence of storage on the unequal distribution of the abundance of miRNA families in all PCs (Figure 1). For example, the largest mir-486 family showed declines in expression, losing the most abundant position on PC-3 to the mir-423 family. The mir-191 family was replaced by members of the let-7 family on PC-2, which are very common in platelets [50]. Probably, post-transcriptional changes influenced the biogenesis and stability of miRNA during storage, as has been shown in studies that used molecular changes in DICER1 to reduce the number of miRNAs that strongly regulated platelet reactivity [51,52].

The measurement of miRNAs expression in the PCs is a variable that we have demonstrated to be associated with the quality of these blood components. When we evaluated the expression levels of miRNA in PCs using computational methodologies, we concluded that, in clinical practice, miRNAs are a very useful tool for testing PC bags that are close to expiration date during storage in a blood bank.

In this study, we found a large number of miRNAs that are candidates as storage damage biomarkers that can replace miR-127, miR-191, and miR-320a miRNAs in clinical trials, which were found in our first study, especially miR-191 which has been used as an internal control for qPCR validation analysis [20].

In addition, we selected six new miRNAs, of the most expressed RNAs, for further validation by qPCR. Relative quantification indicates decreased expression levels of miR-486-5p, miR-92a-3p, miR-103a-3p, miR-151a-3p, miR-181a-5p, and miR-221-3p from the fourth to the fifth day (Figure 3). We also highlighted that this decrease occurred more accentuated for miR-486-5p, which was more expressed in the sRNA-Seq data (Table 2). Additionally, all six miRNAs increased their levels of expression on PC-7 (Figure 3).

We applied computational biology simulations (hierarchical grouping and PCA analysis) to the data generated by sRNA-Seq and qPCR which revealed how the increase in platelet storage time caused changes in the miRNA profiles confirmed in the validation. These computational methodologies have resulted in more accurately identifying miRNAs located in different groups based on the days of storage [53]. In our previous study, we used these methodologies which identified changes in the expression profiles of 14 miRNAs that were associated with PSL [21]. In this current study, we confirmed that changes in the profiles of the new miRNAs correlated with the instability of the half-life of these transcripts on the fourth day, which coincided with the time of onset of PSL. For example, PC bags that are tested and confirm that the expression of miRNAs (miR-151a-3p, miR-103a-3p, and miR-221-3p) is <80% of the expression of (miR-486-5p, miR-92a-3p, and miR-181a-5p) means that there are storage lesions.

The miRNA’s stability varies widely, with half-lives of ~1.5 h, more than 13 h, and up to 48 h, in human biofluids [54,55]. Measuring the relative levels of miRNA in PC is subject to some challenges that need to be taken into account, because the relative stability of miRNAs has implications for their ability to transfer regulatory information, as they are very short and have highly divergent sequences, with a wide variation of the GC content that can favor the different hybridization properties among different miRNA sequences [55].

In a blood bank, the analytical method for testing PCs can be implemented quickly and with low cost to test PC bags stored for more than four days whihc still contain physiologically normal platelets. The durability of platelet physiology depends on individuals with ideal suboptimal health status (SHS), which is considered to be a subclinical and reversible stage of chronic disease. Individuals with SHS can have a progressive accumulation of senescent cells and a relative shortening of the telomeres that produces the early biological aging of platelets [56,57,58].

The increase of miRNA levels in the PCs suggests that after platelet activation they stabilize within the circulating MPs for their transport of action [7,13,59], undergoing changes in their profiles and using selective platelet packaging pathway for MPs [13,60]. For example, we justify expression changes on several PCs, based on the dominant expression pattern in 5p-arm about 3p-arm (Figure 5B). The density measurement confirmed a significant difference in the level of expression, tens or hundreds of times greater in the 5p-arm than in the 3p-arm, as has been observed in other studies [61,62,63].

Our global estimates of miRNAs expression on all PCs pointed to a decline in this dominant pattern from PC-2 to PC-5, but only increased on PC-7 (Table 3). We found several non-model and length variants, positively correlated with recently emerged miRNAs (miR-486-5p, miR-92a-3p, miR-103a-3p, miR-151a-3p, miR-181a-5p, and miR-221-3p), which have not yet been reported in other platelet miRNomes (complete sequencing of miRNAs) and provide greater quality and innovation to the analytical test mentioned in that study.

Our analysis of miRNA–gene functional interaction, pointed to the existence of a molecular regulation mechanism in platelets, which was inferred based on the topology of the interaction network formed by recently emerged miRNAs (miR-103a-3p, miR-423-5p, and miR-92a-3p) and conserved miRNAs of the let-7 family interacting with the YOD1 gene, a desubiquitinating enzyme that is very expressed in platelet hyperactivity [56]. We also identified the functional roles of significant target genes in signaling pathways, cell cycle, stress response, platelet activation, and cancer.

A limitation of this study is the relatively small number of miRNAs investigated, only 20 more expressed, among which, some have been intensively reviewed by the literature [7,30,64,65,66]. Our results also provided a panel of miRNAs that have had their functions elucidated in platelets such as miR-223 [24,66], miR-20a [23] miR-126 [67], miR-10a/miR-10b [68], miR-326 [69], miR-150/miR-501/miR-338-5p/miR-432-5p/miR-411-5p [21], miR-570 [18], miR-495 [70], and miR-21/miR-27b [71]. For example, specific cold storage conditions caused changes in miRNA expressions, increasing levels of miR-20a/miR-10a/miR-16-2/miR-223, which correlated with the quality of platelets under specific conditions of storage [23]. Other miRNAs have been found to play an important role in platelet apoptosis stored as miR-326/miR-570 [18]. Increased expression of miR-21 and miR-27b were found in activated platelet microparticles caused by cooling [71]. In addition to these, there are a variety of new miRNAs that have not yet been reported in the literature (Supplementary Materials S2).

In the future, our investigations should be repeated in a larger number of samples, studying the sixth day of storage (not carried out with the current data). Fresh platelets (PC-0) should also be studied to obtain a broader profile of expression variation with storage days. The option to extend the study after seven days of storage would also be an advantage.

In summary, our results have a promising application in transfusion medicine, because we describe a new collection of miRNAs (miR-486-5p, miR-92a-3p, miR-103a-3p, miR-151a-3p, miR-181a-5p, and miR-221-3p) that shows a sensitivity expression pattern due to biological platelet changes during storage. These miRNAs could be applied, in blood banks, as potential biomarkers to also measure the quality and viability of the PC during storage.

Supplementary Materials

The following are available online https://www.mdpi.com/2218-273X/10/8/1173/s1, File S1: miRNAs-canonicos.xlsx, File S2: Mature.iso.xlsx, File S3: Enrichment analysis.xlsx.

Author Contributions

Conceptualization, J.H.d.S.M. and C.d.F.A.M.-N.; Writing—original draft preparation, J.H.D.S.M. and C.D.F.A.M.-N.; Writing—review and editing, J.H.D.S.M., C.D.F.A.M.-N., and R.M.R.B.; Creation of figures, J.H.D.S.M. and C.D.F.A.M.-N.; Funding acquisition, R.M.R.B. All authors have read and agreed to the published version of the manuscript.

Funding

This study was supported by Brazilian funding agencies National Counsel of Technological and Scientific Development (CNPq; to C.d.F.A.M.-N. and to R.M.R.B.) and Coordination for the Improvement of Higher Education Personnel (CAPES; to J.H.d.S.M. and C.d.F.A.M.-N.), as well as PROPESP/UFPA for payment of the publication fees.

Conflicts of Interest

The authors declare no conflict of interest. The funders had no role in the design of the study; in the collection, analyses, or interpretation of data; in the writing of the manuscript, or in the decision to publish the results.

References

  • 1.Six K.R., Compernolle V., Feys H.B. Platelet Biochemistry and Morphology after Cryopreservation. Int. J. Mol. Sci. 2020;21:935. doi: 10.3390/ijms21030935. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 2.Murphy S., Gardner F.H. Platelet storage at 22°C; metabolic, morphologic, and functional studies. J. Clin. Investig. 1971;50:370–377. doi: 10.1172/JCI106504. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 3.Handigund M., Bae T.W., Lee J., Cho Y.G. Evaluation of in vitro storage characteristics of cold stored platelet concentrates with N acetylcysteine (NAC) Transfus. Apher. Sci. 2016;54:127–138. doi: 10.1016/j.transci.2016.01.006. [DOI] [PubMed] [Google Scholar]
  • 4.Dasgupta S.K., Argaiz E.R., Mercado J.E.C., Maul H.O.E., Garza J., Enriquez A.B., Abdel-Monem H., Prakasam A., Andreeff M., Thiagarajan P. Platelet senescence and phosphatidylserine exposure. Transfusion. 2010;50:2167–2175. doi: 10.1111/j.1537-2995.2010.02676.x. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 5.Cho J., Kim H., Song J., Cheong J.-W., Shin J.W., Yang W.I., Kim H.O. Platelet storage induces accelerated desialylation of platelets and increases hepatic thrombopoietin production. J. Transl. Med. 2018;16:199. doi: 10.1186/s12967-018-1576-6. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 6.Ministério da Saúde Regulamento técnico de procedimentos hemoterápicos. [(accessed on 11 May 2020)]; Available online: http://bvsms.saude.gov.br/bvs/saudelegis/gm/2016/prt0158_04_02_2016.html.
  • 7.Yan Y., Zhang J., Zhang Q., Chen Y., Zhu X., Xia R. The role of microRNAs in platelet biology during storage. Transfus. Apher. Sci. 2017;56:147–150. doi: 10.1016/j.transci.2016.10.010. [DOI] [PubMed] [Google Scholar]
  • 8.Estcourt L.J., Malouf R., Hopewell S., Trivella M., Doree C., Stanworth S.J., Murphy M.F. Pathogen-reduced platelets for the prevention of bleeding. Cochrane Database Syst. Rev. 2017;2017 doi: 10.1002/14651858.CD009072.pub3. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 9.Schubert P., Devine D.V. Towards targeting platelet storage lesion-related signaling pathways. Blood Transfus. 2010;8:69–72. doi: 10.2450/2010.011S. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 10.Mittal K., Kaur R. Platelet storage lesion: An update. Asian J. Transfus. Sci. 2015;9:1–3. doi: 10.4103/0973-6247.150933. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 11.Laffont B., Corduan A., Ple H., Duchez A.-C., Cloutier N., Boilard E., Provost P. Activated platelets can deliver mRNA regulatory Ago2.microRNA complexes to endothelial cells via microparticles. Blood. 2013;122:253–261. doi: 10.1182/blood-2013-03-492801. [DOI] [PubMed] [Google Scholar]
  • 12.Boilard E., Belleannée C. (Dicer)phering roles of microRNA in platelets. Blood. 2016;127:1733–1734. doi: 10.1182/blood-2016-01-694893. [DOI] [PubMed] [Google Scholar]
  • 13.Diehl P., Fricke A., Sander L., Stamm J., Bassler N., Htun N., Ziemann M., Helbing T., El-Osta A., Jowett J.B.M., et al. Microparticles: Major transport vehicles for distinct microRNAs in circulation. Cardiovasc. Res. 2012;93:633–644. doi: 10.1093/cvr/cvs007. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 14.Shrivastava M. The platelet storage lesion. Transfus. Apher. Sci. 2009;41:105–113. doi: 10.1016/j.transci.2009.07.002. [DOI] [PubMed] [Google Scholar]
  • 15.Van der Meer P.F. Platelet concentrates, from whole blood or collected by apheresis? Transfus. Apher. Sci. 2013;48:129–131. doi: 10.1016/j.transci.2013.02.004. [DOI] [PubMed] [Google Scholar]
  • 16.Ravi S., Chacko B., Sawada H., Kramer P.A., Johnson M.S., Benavides G.A., O’Donnell V., Marques M.B., Darley-Usmar V.M. Metabolic plasticity in resting and thrombin activated platelets. PLoS ONE. 2015;10:e0123597. doi: 10.1371/journal.pone.0123597. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 17.Ravi S., Chacko B., Kramer P.A., Sawada H., Johnson M.S., Zhi D., Marques M.B., Darley-Usmar V.M. Defining the effects of storage on platelet bioenergetics: The role of increased proton leak. Biochim. Biophys. Acta Mol. Basis Dis. 2015;1852:2525–2534. doi: 10.1016/j.bbadis.2015.08.026. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 18.Dahiya N., Sarachana T., Kulkarni S., Wood Iii W.H., Zhang Y., Becker K.G., Wang B.-D., Atreya C.D. miR-570 interacts with mitochondrial ATPase subunit g (ATP5L) encoding mRNA in stored platelets. Platelets. 2016;7104:1–8. doi: 10.1080/09537104.2016.1203405. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 19.Bartel D.P. Metazoan MicroRNAs. Cell. 2018;173:20–51. doi: 10.1016/j.cell.2018.03.006. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 20.Pontes T.B., Moreira-Nunes C.D.F.A., Maués J.H.D.S., Lamarão L.M., De Lemos J.A.R., Montenegro R.C., Burbano R.M.R. The miRNA Profile of Platelets Stored in a Blood Bank and Its Relation to Cellular Damage from Storage. PLoS ONE. 2015;10:e0129399. doi: 10.1371/journal.pone.0129399. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 21.Maués J.H.D.S., Moreira-Nunes C.D.F.A., Pontes T.B., Vieira P.C.M., Montenegro R.C., Lamarão L.M., Lima E.M., Burbano R.M.R. Differential Expression Profile of MicroRNAs During Prolonged Storage of Platelet Concentrates as a Quality Measurement Tool in Blood Banks. OMICS A J. Integr. Biol. 2018;22:653–664. doi: 10.1089/omi.2018.0126. [DOI] [PubMed] [Google Scholar]
  • 22.Diallo I., Benmoussa A., Laugier J., Osman A., Hitzler W.E., Provost P. Platelet Pathogen Reduction Technologies Alter the MicroRNA Profile of Platelet-Derived Microparticles. Front. Cardiovasc. Med. 2020;7:1–9. doi: 10.3389/fcvm.2020.00031. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 23.Mukai N., Nakayama Y., Ishi S., Murakami T., Ogawa S., Kageyama K., Murakami S., Sasada Y., Yoshioka J., Nakajima Y. Cold storage conditions modify microRNA expressions for platelet transfusion. PLoS ONE. 2019;14:e0218797. doi: 10.1371/journal.pone.0218797. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 24.Nagalla S., Shaw C., Kong X., Kondkar A.A., Edelstein L.C., Ma L., Chen J., McKnight G.S., López J.A., Yang L., et al. Platelet microRNA-mRNA coexpression profiles correlate with platelet reactivity. Blood. 2011;117:5189–5197. doi: 10.1182/blood-2010-09-299719. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 25.Teruel-Montoya R., Kong X., Abraham S., Ma L., Kunapuli S.P., Holinstat M., Shaw C.A., McKenzie S.E., Edelstein L.C., Bray P.F. MicroRNA Expression Differences in Human Hematopoietic Cell Lineages Enable Regulated Transgene Expression. PLoS ONE. 2014;9:e102259. doi: 10.1371/journal.pone.0102259. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 26.Mukai N., Nakayama Y., Ishi S., Ogawa S., Maeda S., Anada N., Murakami S., Mizobe T., Sawa T., Nakajima Y. Changes in MicroRNA Expression Level of Circulating Platelets Contribute to Platelet Defect After Cardiopulmonary Bypass. Crit. Care Med. 2018;46:e761–e767. doi: 10.1097/CCM.0000000000003197. [DOI] [PubMed] [Google Scholar]
  • 27.Aparicio-Puerta E., Lebrón R., Rueda A., Gómez-Martín C., Giannoukakos S., Jaspez D., Medina J.M., Zubkovic A., Jurak I., Fromm B., et al. sRNAbench and sRNAtoolbox 2019: Intuitive fast small RNA profiling and differential expression. Nucleic Acids Res. 2019;47:W530–W535. doi: 10.1093/nar/gkz415. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 28.Rueda A., Barturen G., Lebrón R., Gómez-Martín C., Alganza Á., Oliver J.L., Hackenberg M. sRNAtoolbox: An integrated collection of small RNA research tools. Nucleic Acids Res. 2015;43:W467–W473. doi: 10.1093/nar/gkv555. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 29.Kozomara A., Birgaoanu M., Griffiths-Jones S. miRBase: From microRNA sequences to function. Nucleic Acids Res. 2019;47:D155–D162. doi: 10.1093/nar/gky1141. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 30.Maués J.H.D.S., Aquino Moreira-Nunes C.D.F., Rodriguez Burbano R.M. MicroRNAs as a Potential Quality Measurement Tool of Platelet Concentrate Stored in Blood Banks—A Review. Cells. 2019;8:1256. doi: 10.3390/cells8101256. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 31.Morin R.D., O’Connor M.D., Griffith M., Kuchenbauer F., Delaney A., Prabhu A.-L., Zhao Y., McDonald H., Zeng T., Hirst M., et al. Application of massively parallel sequencing to microRNA profiling and discovery in human embryonic stem cells. Genome Res. 2008;18:610–621. doi: 10.1101/gr.7179508. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 32.Langmead B., Trapnell C., Pop M., Salzberg S.L. Ultrafast and memory-efficient alignment of short DNA sequences to the human genome. Genome Biol. 2009;10:R25. doi: 10.1186/gb-2009-10-3-r25. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 33.Agarwal V., Bell G.W., Nam J.-W., Bartel D.P. Predicting effective microRNA target sites in mammalian mRNAs. Elife. 2015;4:1–38. doi: 10.7554/eLife.05005. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 34.Huang H.-Y., Lin Y.-C.-D., Li J., Huang K.-Y., Shrestha S., Hong H.-C., Tang Y., Chen Y.-G., Jin C.-N., Yu Y., et al. miRTarBase 2020: Updates to the experimentally validated microRNA–target interaction database. Nucleic Acids Res. 2019;48:D148–D154. doi: 10.1093/nar/gkz896. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 35.Chen Y., Wang X. miRDB: An online database for prediction of functional microRNA targets. Nucleic Acids Res. 2020;48:D127–D131. doi: 10.1093/nar/gkz757. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 36.Ding J., Li X., Hu H. TarPmiR: A new approach for microRNA target site prediction. Bioinformatics. 2016;32:2768–2775. doi: 10.1093/bioinformatics/btw318. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 37.Sticht C., De La Torre C., Parveen A., Gretz N. miRWalk: An online resource for prediction of microRNA binding sites. PLoS ONE. 2018;13:e0206239. doi: 10.1371/journal.pone.0206239. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 38.Chin C.H., Chen S.H., Wu H.H., Ho C.W., Ko M.T., Lin C.Y. cytoHubba: Identifying hub objects and sub-networks from complex interactome. BMC Syst. Biol. 2014;8:S11. doi: 10.1186/1752-0509-8-S4-S11. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 39.Huang D.W., Sherman B.T., Lempicki R.A. Systematic and integrative analysis of large gene lists using DAVID bioinformatics resources. Nat. Protoc. 2009;4:44–57. doi: 10.1038/nprot.2008.211. [DOI] [PubMed] [Google Scholar]
  • 40.Ashburner M., Ball C.A., Blake J.A., Botstein D., Butler H., Cherry J.M., Davis A.P., Dolinski K., Dwight S.S., Eppig J.T., et al. Gene Ontology: Tool for the unification of biology. Nat. Genet. 2000;25:25–29. doi: 10.1038/75556. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 41.Kanehisa M., Sato Y., Furumichi M., Morishima K., Tanabe M. New approach for understanding genome variations in KEGG. Nucleic Acids Res. 2019;47:D590–D595. doi: 10.1093/nar/gky962. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 42.Lê S., Josse J., Husson F. FactoMineR: An R package for multivariate analysis. J. Stat. Softw. 2008;25:1–18. doi: 10.18637/jss.v025.i01. [DOI] [Google Scholar]
  • 43.Ovadya Y., Landsberger T., Leins H., Vadai E., Gal H., Biran A., Yosef R., Sagiv A., Agrawal A., Shapira A., et al. Impaired immune surveillance accelerates accumulation of senescent cells and aging. Nat. Commun. 2018;9:5435. doi: 10.1038/s41467-018-07825-3. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 44.Sut C., Tariket S., Aubron C., Aloui C., Hamzeh-Cognasse H., Berthelot P., Laradi S., Greinacher A., Garraud O., Cognasse F. The Non-Hemostatic Aspects of Transfused Platelets. Front. Med. 2018;5:42. doi: 10.3389/fmed.2018.00042. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 45.Delobel J., Rubin O., Prudent M., Crettaz D., Tissot J.-D., Lion N. Biomarker analysis of stored blood products: Emphasis on pre-analytical issues. Int. J. Mol. Sci. 2010;11:4601–4617. doi: 10.3390/ijms11114601. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 46.Cookson P., Sutherland J., Turner C., Bashir S., Wiltshire M., Hancock V., Smith K., Cardigan R. Platelet apoptosis and activation in platelet concentrates stored for up to 12 days in plasma or additive solution. Transfus. Med. 2010;20:392–402. doi: 10.1111/j.1365-3148.2010.01034.x. [DOI] [PubMed] [Google Scholar]
  • 47.Árnason N.Á., Sigurjónsson Ó.E. New strategies to understand platelet storage lesion. ISBT Sci. Ser. 2017;12:496–500. doi: 10.1111/voxs.12394. [DOI] [Google Scholar]
  • 48.Edelstein L.C., Bray P.F. MicroRNAs in platelet production and activation. Blood. 2011;117:5289–5296. doi: 10.1182/blood-2011-01-292011. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 49.Yang A., Troup M., Ho J.W.K. Scalability and Validation of Big Data Bioinformatics Software. Comput. Struct. Biotechnol. J. 2017;15:379–386. doi: 10.1016/j.csbj.2017.07.002. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 50.Plé H., Landry P., Benham A., Coarfa C., Gunaratne P.H., Provost P. The Repertoire and Features of Human Platelet microRNAs. PLoS ONE. 2012;7:e50746. doi: 10.1371/journal.pone.0050746. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 51.Kannan M., Mohan K.V.K., Kulkarni S., Atreya C. Membrane array-based differential profiling of platelets during storage for 52 miRNAs associated with apoptosis. Transfusion. 2009;49:1443–1450. doi: 10.1111/j.1537-2995.2009.02140.x. [DOI] [PubMed] [Google Scholar]
  • 52.Rowley J.W., Chappaz S., Corduan A., Chong M.M.W.W., Campbell R., Khoury A., Manne B.K., Wurtzel J.G.T.T., Michael J.V., Goldfinger L.E., et al. Dicer1-mediated miRNA processing shapes the mRNA profile and function of murine platelets. Blood. 2016;127:1743–1752. doi: 10.1182/blood-2015-07-661371. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 53.Atreya C.D. Ingenuity Pathway Analysis of miRnas and mRNAs in Stored Platelets Identifies the Potential of miRNAs in Regulating Platelet Functions Relevant to Storage Lesions. Hematol. Blood Transfus. Disord. 2016;3:1–5. doi: 10.24966/HBTD-2999/100012. [DOI] [Google Scholar]
  • 54.Coenen-Stass A.M.L., Pauwels M.J., Hanson B., Martin Perez C., Conceição M., Wood M.J.A., Mäger I., Roberts T.C. Extracellular microRNAs exhibit sequence-dependent stability and cellular release kinetics. RNA Biol. 2019;16:696–706. doi: 10.1080/15476286.2019.1582956. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 55.Blondal T., Jensby Nielsen S., Baker A., Andreasen D., Mouritzen P., Wrang Teilum M., Dahlsveen I.K. Assessing sample and miRNA profile quality in serum and plasma or other biofluids. Methods. 2013;59:S1–S6. doi: 10.1016/j.ymeth.2012.09.015. [DOI] [PubMed] [Google Scholar]
  • 56.Wang W., Yan Y. Suboptimal health: A new health dimension for translational medicine. Clin. Transl. Med. 2012;1:28. doi: 10.1186/2001-1326-1-28. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 57.Glade M.J. Oxidative Telomere Attrition, Nutritional Antioxidants And Biological Aging. Int. J. Nutr. 2015;1:1–37. doi: 10.14302/issn.2379-7835.ijn-14-606. [DOI] [Google Scholar]
  • 58.Alzain M.A., Asweto C.O., Zhang J., Fang H., Zhao Z., Guo X., Song M., Zhou Y., Chang N., Wang Y., et al. Telomere Length and Accelerated Biological Aging in the China Suboptimal Health Cohort: A Case–Control Study. OMICS A J. Integr. Biol. 2017;21:333–339. doi: 10.1089/omi.2017.0050. [DOI] [PubMed] [Google Scholar]
  • 59.Jansen F., Yang X., Proebsting S., Hoelscher M., Przybilla D., Baumann K., Schmitz T., Dolf A., Endl E., Franklin B.S., et al. MicroRNA Expression in Circulating Microvesicles Predicts Cardiovascular Events in Patients With Coronary Artery Disease. J. Am. Heart Assoc. 2014;3:e001249. doi: 10.1161/JAHA.114.001249. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 60.Gibbings D.J., Ciaudo C., Erhardt M., Voinnet O. Multivesicular bodies associate with components of miRNA effector complexes and modulate miRNA activity. Nat. Cell Biol. 2009;11:1143–1149. doi: 10.1038/ncb1929. [DOI] [PubMed] [Google Scholar]
  • 61.Griffiths-Jones S., Hui J.H.L., Marco A., Ronshaugen M. MicroRNA evolution by arm switching. EMBO Rep. 2011;12:172–177. doi: 10.1038/embor.2010.191. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 62.Hu W., Wang T., Yue E., Zheng S., Xu J.H. Flexible microRNA arm selection in rice. Biochem. Biophys. Res. Commun. 2014;447:526–530. doi: 10.1016/j.bbrc.2014.04.036. [DOI] [PubMed] [Google Scholar]
  • 63.Ro S., Park C., Young D., Sanders K.M., Yan W. Tissue-dependent paired expression of miRNAs. Nucleic Acids Res. 2007;35:5944–5953. doi: 10.1093/nar/gkm641. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 64.Dahiya N., Sarachana T., Vu L., Becker K.G., Wood W.H., Zhang Y., Atreya C.D. Platelet MicroRNAs: An Overview. Transfus. Med. Rev. 2015;29:215–219. doi: 10.1016/j.tmrv.2015.08.002. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 65.Lindsay C., Edelstein L. MicroRNAs in Platelet Physiology and Function. Semin. Thromb. Hemost. 2016;42:215–222. doi: 10.1055/s-0035-1570077. [DOI] [PubMed] [Google Scholar]
  • 66.Landry P., Plante I., Ouellet D.L., Perron M.P., Rousseau G., Provost P. Existence of a microRNA pathway in anucleate platelets. Nat. Struct. Mol. Biol. 2009;16:961–966. doi: 10.1038/nsmb.1651. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 67.Willeit P., Zampetaki A., Dudek K., Kaudewitz D., King A., Kirkby N.S., Crosby-Nwaobi R., Prokopi M., Drozdov I., Langley S.R., et al. Circulating microRNAs as novel biomarkers for platelet activation. Circ. Res. 2013;112:595–600. doi: 10.1161/CIRCRESAHA.111.300539. [DOI] [PubMed] [Google Scholar]
  • 68.Zhang Z., Ran Y., Shaw T.S., Peng Y. MicroRNAs 10a and 10b Regulate the Expression of Human Platelet Glycoprotein Ibα for Normal Megakaryopoiesis. Int. J. Mol. Sci. 2016;17:1873. doi: 10.3390/ijms17111873. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 69.Yu S., Huang H., Deng G., Xie Z., Ye Y., Guo R., Cai X., Hong J., Qian D., Zhou X., et al. miR-326 Targets Antiapoptotic Bcl-xL and Mediates Apoptosis in Human Platelets. PLoS ONE. 2015;10:e0122784. doi: 10.1371/journal.pone.0122784. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 70.Edelstein L.C., McKenzie S.E., Shaw C., Holinstat M.A., Kunapuli S.P., Bray P.F. MicroRNAs in platelet production and activation. J. Thromb. Haemost. 2013;11:340–350. doi: 10.1111/jth.12214. [DOI] [PubMed] [Google Scholar]
  • 71.Yuan Z., Wu Q., Chen X., Wei Y. Altered microRNA expression profiles are involved in Storage Lesions of Apheresis Platelet. BioRxiv. 2018 doi: 10.1101/386011. [DOI] [Google Scholar]

Associated Data

This section collects any data citations, data availability statements, or supplementary materials included in this article.

Supplementary Materials


Articles from Biomolecules are provided here courtesy of Multidisciplinary Digital Publishing Institute (MDPI)

RESOURCES